TSEDAY E SIRAK

Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease OWENSBORO, KY NPI 1346348992

General Payments — all program years on this page

$4,416.71

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 270
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $415.83 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $415.8319

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $445.3223
2019 $1,207.5165
2020 $278.4019
2021 $503.8234
2022 $967.6364
2023 $598.2046
2024 $415.8319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1081732027 Lexicon Pharmaceuticals, Inc. $15.58 03/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1081732029 Lexicon Pharmaceuticals, Inc. $16.80 04/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1081732031 Lexicon Pharmaceuticals, Inc. $20.67 06/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087258423 Novartis Pharmaceuticals Corporation $21.99 07/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087258431 Novartis Pharmaceuticals Corporation $17.95 10/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087258435 Novartis Pharmaceuticals Corporation $13.69 12/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1101242258 E.R. Squibb & Sons, L.L.C. $14.34 05/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116131585 Amgen Inc. $15.02 01/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116131591 Amgen Inc. $17.59 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116131599 Amgen Inc. $19.06 03/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116131605 Amgen Inc. $15.12 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117972707 Boehringer Ingelheim Pharmaceuticals, Inc. $14.93 07/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125857398 Alnylam Pharmaceuticals Inc. $19.44 07/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1129455766 Esperion Therapeutics, Inc. $14.48 07/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131546204 PFIZER INC. $23.88 02/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131668918 PFIZER INC. $14.72 06/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141723882 Merck Sharp & Dohme LLC $17.57 03/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141932501 Merck Sharp & Dohme LLC $16.92 01/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154169070 HEARTFLOW, INC. $106.08 10/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.